Cilta-Cel Reverts To Standard Review In EU
Janssen Says Loss Of Fast-Track Status For CAR-T Therapy Was Expected
Janssen says the review at the European Medicines Agency of its marketing authorization application for cilta-cel reverted to standard timelines because the EMA wanted a GMP inspection and provision of a GMP certificate, "which did not allow continuation of the accelerated assessment timetable.”
